ImmunityBio Advances Pipeline with Novel Lymphoma Trial
03.02.2026 - 21:44:05
ImmunityBio has initiated a new clinical study, marking a strategic expansion of its development pipeline. The U.S. biotechnology firm announced the launch of a Phase 2 trial evaluating an experimental cell therapy combination for a specific group of lymphoma patients, notably without the use of chemotherapy. This move tests whether the company’s therapeutic platform can succeed beyond its established bladder cancer indication.
On February 2, 2026, ImmunityBio publicly disclosed the commencement of its ResQ215B study. The trial will enroll patients diagnosed with indolent B-cell non-Hodgkin lymphoma (iNHL), a category of slow-growing lymphatic cancers.
The investigational regimen is a three-part combination therapy:
- CD19 t-haNK: An Read more...
